Business Wire

Elemental Machines Launches Flexible, Multitiered Business Intelligence Platform to Expand Lab Data Insights

21.8.2025 15:00:00 CEST | Business Wire | Press Release

Share

Elemental Machines, a pioneer in life sciences laboratory operational intelligence, announces the launch of its new business intelligence (BI) platform, a multitiered data analysis solution built to empower labs with actionable intelligence at every stage of the data journey.

As the volume and complexity of lab-generated data continue to grow, the need for scalable, customizable analytics platforms has become essential. Elemental Machines’ new BI offerings address this need head-on. Users are empowered to turn millions of data points into clear, meaningful insights that range from individual equipment readings to enterprise-wide performance trends.

“Scientific progress depends on more than just the data you collect; it depends on what you can do with it,” said Sridhar Iyengar, Ph.D., Founder and Chief Strategy & Technology Officer at Elemental Machines. “With our business intelligence platform, we’re helping labs transition from raw data collection to creating a real-world operational impact — whether that means increasing equipment uptime, reducing costs, or making better, more informed decisions, faster.”

The platform offers a flexible, three-tiered model to support labs at every stage of BI maturity:

  • Tier 1: Elemental Machines’ Core Platform —Real-time alerts, configurable operational dashboards, compliance-ready reporting, and visual floorplans for immediate operational awareness
  • Tier 2: Dynamic Data Insights —Performance trend analysis, dynamically customizable dashboards, predictive equipment health scores, and asset utilization optimization
  • Tier 3: Data transfer for enterprise integration —Integrate Elemental Machines’ data with your own enterprise BI tools (e.g., Snowflake, BigQuery, Tableau, Power BI) for advanced analytics, AI/ML applications, and cross-site visibility

“Our goal is to meet every customer where they are, whether they’re just starting to automate compliance reports, or building enterprise-wide digital twins,” said Andrew Eberle, Senior Director of Customer Solutions at Elemental Machines. “The platform adapts to each lab’s size, infrastructure, and goals. This helps teams scale their data usage without overcomplicating their workflow.”

Elemental Machines’ platform is already helping labs monitor asset usage, flag anomalies early, and support lab operations teams in delivering more efficient, reliable outcomes. To explore the full BI offering, view the infographic and learn more at elementalmachines.com.

About Elemental Machines

Elemental Machines’ Intelligent Operations Platform transforms raw lab and facility data into intelligence you can act on. Built by scientists and engineers who understand the demands of modern research and manufacturing environments, we connect the physical and digital worlds to simplify, optimize, and future-proof operations. From incubators to enterprise-level sites, our ecosystem combines wireless sensors, utilization tracking, custom dashboards, interactive floorplans, business intelligence tools, and seamless integrations with systems like LIMS, MES, QMS, CMMS, and ELNs, giving teams complete visibility, predictive insights, and audit-ready compliance tools. Leaders in science, facilities, and technology worldwide trust Elemental Machines to help them act faster, reduce operational risk, and shift from reactive to proactive management. With the industry’s most expansive integration library and a robust partner ecosystem, we empower organizations to accelerate innovation, ensure scientific integrity, and get more value from every asset.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250821321306/en/

Contacts

MEDIA CONTACT:
Gabe Martinez
SCORR Marketing
+1 308.338.2304
pr@scorrmarketing.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye